Relapsing Remitting Multiple Sclerosis Clinical Trial
The purpose of this study is to determine if using Avonex in combination with Zocor is a safe and effective therapy for subjects with relapsing remitting multiple sclerosis.
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the Central Nervous
System (CNS). There are many forms of MS; althoughthe majority are Relapsing Remitting
(RRMS) representing approximately 80% of the cases. The disease appears to be more
inflammatory in RRMS as manisfested by an increase inGadolinium enhancement on MRI and an
increase in inflammatory bioassay markers.
Zocor is in a class of drugs (statins) that are used to lower cholesterol. Statins also have
an anti-inflammatory effect on the CNS. Zocor has been shown in a small clinical trial to
reduce the number of new MRI-detected brain lesions over a six month treatment period in
patients with RRMS. This study is to evaluate the safety of combining Avonex with Zocor for
a a period of fourteen months in patients with RRMS and to evaluate the effect of treatment
on new or enlarging lesions as measured by MRI.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01945359 -
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
|
N/A | |
| Completed |
NCT01456416 -
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
|
Phase 4 | |
| Completed |
NCT01450124 -
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
|
Phase 2 | |
| Recruiting |
NCT05277740 -
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
|
||
| Completed |
NCT03718247 -
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
|
||
| Active, not recruiting |
NCT03471338 -
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
|
N/A | |
| Recruiting |
NCT03004079 -
Clinical Importance of Glucose Regulation in Relapsing MS
|
||
| Terminated |
NCT02266121 -
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
|
N/A | |
| Completed |
NCT01963611 -
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
|
Phase 2 | |
| Active, not recruiting |
NCT01464905 -
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
| Completed |
NCT01225289 -
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
|
Phase 4 | |
| Completed |
NCT00203086 -
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00616187 -
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT06083753 -
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
| Recruiting |
NCT06159712 -
Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT04604041 -
Investigation of Subclinical Markers of Multiple Sclerosis
|
||
| Terminated |
NCT03536559 -
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02490982 -
Teriflunomide Observational Effectiveness Study
|
||
| Withdrawn |
NCT00939549 -
High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
|
Phase 2 |